Clinical trials: Anti-Retroviral Agents
Drug Resistance
An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy
Hypothesis Nevirapine resistance developed in women and infants in the HIVNET 006 and 012 cohorts as a consequence of use of an agent with a long t½ as monotherapy in individuals with high viral loads.
- Trial name
- NCT00193947
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- University Health Network, Toronto
HIV-1
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
Background: Antiretroviral therapy (ART) can suppress HIV to undetectable levels in people, but the virus rebounds quickly if the drug treatment is stopped; this is because HIV can remain dormant in a pool of blood cells called…
- Trial name
- NCT05612178
- Testing
- 3BNC117-LS, 10-1074-LS, Sterile Saline
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Toxicity
Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients
The purpose of this study is to determine the frequency of renal and bone toxicity in HIV infected patients receiving antiretroviral therapy, and the outcome in terms of treatment change or/and virological failure, in relation…
- Trial name
- ComorVIH (NCT02116751)
- Where
- Spain
- Volunteers
- 306 people
- Sponsor
- Asociacion para el Estudio de las Enfermedades Infecciosas
Hepatitis B, Human Immunodeficiency Virus
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.
- Conditions
- Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
- Trial name
- NCT00782301
- Testing
- maraviroc, etravirine
- Where
- 18 sites in United States, Canada and 1 more
- Sponsor
- ViiV Healthcare
Tuberculosis
Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
Higher doses of rifampicin has been associated with a faster drop in bacterial load over time, and shorter treatment regimens with high dose rifampicin are being proposed.
- Trial name
- SAEFRIF (NCT03982277)
- Testing
- Rifampin 300 Mg Oral Capsule
- Where
- Uganda
- Volunteers
- 130 people
- Sponsor
- Makerere University
HIV
Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting
The frequency of neurological and psychiatric complaints for participants taking rilpivirine, elvitegravir, or dolutegravir reaches on average 20-30% during clinical trials.
- Trial name
- NEPAL (NCT02882230)
- Testing
- prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
HIV-1
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of…
- Trial name
- MODERN (NCT01345630)
- Testing
- Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg
- Where
- 177 sites in United States, Australia and 17 more
- Volunteers
- 813 people
- Sponsor
- ViiV Healthcare
HIV-1-infection
Mathematical Modeling of the HIV Transmission Risk After Initiation of Antiretroviral Therapy in naïve HIV-infected
The objective of this study is to explore the impact of initiation of ART with different regimens in naïve MSM (in the setting of acute and chronic HIV-infection) on the probability of transmission of HIV by mathematical modeling.
- Trial name
- MIAMI (NCT03183154)
- Testing
- no intervention
- Where
- Spain
- Volunteers
- 1,831 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
HIV Infections
Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis
The study compares the adherence of 240 HIV-negative subjects randomly assigned to 2 different antiretroviral therapies for 28 days after accidental exposure to HIV.
- Trial name
- NCT00385645
- Testing
- Combivir+Kaletra, Combivir+Reyataz
- Where
- 7 sites in Spain
- Volunteers
- 255 people
- Sponsor
- Hospital Clinic of Barcelona
HIV Infections
A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.
Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients
- Trial name
- NCT00144105
- Testing
- TPV500mg/RTV200mgBID, TPV500mg/RTV100mgBID, LPV400mg/RTV100mgBID
- Where
- 81 sites in Argentina, Australia and 13 more
- Volunteers
- 562 people
- Sponsor
- Boehringer Ingelheim
HIV
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
The goal of Suubi+Adherence is to examine the impact and cost associated with an innovative intervention to increase adherence to HIV treatment for HIV-infected adolescents.
- Trial name
- NCT01790373
- Testing
- Suubi+Adherence, Bolstered Standard of Care
- Where
- 2 sites in United States, Uganda
- Volunteers
- 702 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Human Immunodeficiency Virus, HIV Infections
Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring
Background Low concentrations of protease inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs) are associated with an increased risk of virological failure.
- Trial name
- TDM (NCT00836212)
- Testing
- Reducing dose of Lopinavir, Reducing dose of efavirenz
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University Hospital, Geneva
HIV
Analysis of HIV-1 Replication During Antiretroviral Therapy
This study will determine if the level of virus in HIV-infected patients taking antiretroviral medications for prolonged periods decreases or persists at a stable level.
- Trial name
- NCT00767312
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Understanding the Increased Risk of Cardiovascular Disease in People With HIV
HIV is a virus that can lead to acquired immunodeficiency syndrome (AIDS), a disease for which there is not yet a cure. Antiretroviral therapy (ART) has proven an effective treatment for inhibiting the replication of HIV…
- Trial name
- NCT00577681
- Testing
- Antiretroviral Therapy (ART)
- Volunteers
- 5,472 people
- Sponsor
- University of Minnesota
HIV Infections
A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
To compare the proportion of patients whose plasma HIV-1 RNA is below 500 copies/ml after 16 weeks of treatment. To assess the safety, toxicity, and tolerance of each treatment arm.
- Trial name
- NCT00000892
- Testing
- Ritonavir, Nelfinavir mesylate, Levocarnitine
- Where
- 45 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic HIV Infection, HCV Coinfection
HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
This study examines the impact of fosamprenavir as part of an ART on virological, immunological and clinical parameters of genotype 1 HCV infection in HIV co-infected subjects.
- Trial name
- FOSTER-C (NCT01222611)
- Testing
- Fosamprenavir
- Where
- 6 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
The purpose of this study is to identify and provide immediate antiretroviral therapy to a cohort of HIV-infected individuals with very early HIV infection (estimated date of infection within the last 90 days).
- Trial name
- DGVTAF (NCT02656511)
- Testing
- Dolutegravir, Emtricitabine/Tenofovir
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco
HIV Infection
Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)
This study will examine whether interleukin-2 (IL-2) plus antiretroviral therapy (ART) slows HIV disease progression in patients with low CD4+ T cell counts compared with patients taking ART alone.
- Trial name
- SILCAAT (NCT00013611)
- Testing
- Proleukin
- Where
- United States
- Volunteers
- 1,695 people
- Sponsor
- University of Minnesota
HIV-infection, Coronary Heart Disease
A Prospective Observational Trial to Determine Cardiovascular Diseases in HIV-infected Patients
The HIV/HEART study (HIVH) is an ongoing, prospective, multicentre trial that was conducted to assess the incidence, the prevalence and the clinical course of cardiovascular diseases (CVD) in HIV-infected patients.
- Conditions
- HIV-infection, Coronary Heart Disease, Myocardial Infarction, HIV-encephalopathy
- Trial name
- HIV-HEART10 (NCT02291081)
- Testing
- Comprehensive non invasive cardiovascular examination
- Where
- 7 sites in Germany
- Volunteers
- 1,519 people
- Sponsor
- University Hospital, Essen
HIV Infection
Same-day ART Initiation Versus Standard of Care After Positive HIV-test Result in Rural Lesotho
The CASCADE-trial is a two-armed open-label randomized controlled trial conducted in rural Lesotho. Participants who were tested HIV-positive during community-based HIV testing and counseling campaigns are randomized to the…
- Trial name
- CASCADE (NCT02692027)
- Testing
- Same-day ART initiation, Standard of care
- Where
- Lesotho
- Volunteers
- 276 people
- Sponsor
- Swiss Tropical & Public Health Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.